RACHEL LANGLAND
Allopathic & Osteopathic Physicians|Family Medicine GLENDALE, AZ NPI 1164411849
Browse related groups: Allopathic & Osteopathic Physicians|Family Medicine AZ Takeda Pharmaceuticals U.S.A., Inc. All categories
General Payments — all program years on this page
$84,211.50
- Category: General Payments
- Program years: PY2018–2024
- Record count: 178
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $9,686.26 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,531.69 | 5 |
| Food and Beverage | $139.51 | 1 |
| Education | $15.06 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $9,546.75 | 7 |
| Edwards Lifesciences Corporation | $139.51 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1137613489 | Takeda Pharmaceuticals U.S.A., Inc. | $2,006.67 | 01/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1137613493 | Takeda Pharmaceuticals U.S.A., Inc. | $2,006.67 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1137613497 | Takeda Pharmaceuticals U.S.A., Inc. | $2,006.67 | 03/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1137613501 | Takeda Pharmaceuticals U.S.A., Inc. | $2,006.67 | 04/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1137613504 | Takeda Pharmaceuticals U.S.A., Inc. | $7.53 | 04/19/2024 | Education | Undisputed | 01/23/2026 | View at CMS |
| 1137613508 | Takeda Pharmaceuticals U.S.A., Inc. | $7.53 | 04/22/2024 | Education | Undisputed | 01/23/2026 | View at CMS |
| 1137613511 | Takeda Pharmaceuticals U.S.A., Inc. | $1,505.01 | 05/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1138863883 | Edwards Lifesciences Corporation | $139.51 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.